Company Overview
Primmune Therapeutics is a biotechnology company based in San Diego, California, specializing in the development of therapies that harness the innate immune system to treat cancers and viral diseases. Established by experts in structure-based drug design, the company focuses on small molecule therapies, particularly those targeting the Toll-like receptor 7 (TLR7) with their lead candidate, PRTX007. This oral therapeutic has demonstrated promising results in preclinical and clinical settings by activating the immune system without triggering systemic inflammatory responses, positioning it as a pivotal treatment for virally-mediated cancers such as oropharyngeal and hepatocellular carcinoma. These cancers are notably associated with human papillomavirus (HPV) and hepatitis C virus (HCV).
Primmune Therapeutics operates with a streamlined team of nine employees and reports an annual revenue of approximately $775,000. It is recognized as one of the sector's leading startups.
Financial Performance
Primmune Therapeutics has successfully executed several financing rounds to advance its research initiatives:
- Series A Financing: $27.4 million closed in October 2020.
- Seed Financing: $7 million secured for the development of TLR7 immunotherapies.
- Government Contract: $22.5 million obtained from the Defense Threat Reduction Agency for advancing PRTX007 as a treatment for Lassa fever.
Key Executives and Team
- Charles McDermott: President, CEO, and Director. With over 25 years of life science experience, McDermott has been instrumental in driving strategic initiatives in drug discovery.
- James Appleman, Ph.D.: Senior Vice President, Research & Development, Chief Scientific Officer, Cofounder, and Director. He brings nearly 30 years of successful drug discovery experience and was a cofounder of eFFECTOR Therapeutics.
- Paulo Rangel: Chief Business Officer and Cofounder. He is recognized for his expertise in pharmaceutical partnerships and global licensing.
- Curtis Scribner, M.D.: Chief Medical Officer. Scribner offers a wealth of experience in drug development and internal medicine.
- Marc Veale: Chief Financial Officer. With over 25 years in finance and accounting within life sciences, Veale plays a pivotal role in Primmune's financial strategies.
- Stephen Webber, Ph.D.: Vice President, Medicinal Chemistry, and Cofounder. Webber has made significant contributions to medicinal chemistry.
- Scott Zook: Senior Vice President, Global Manufacturing. Zook has over 27 years in drug development, focusing on CMC strategies.
Strategic Focus and Therapeutic Development
Primmune's strategy is centered on developing treatments for virally-mediated cancers, particularly those associated with HPV and HCV, by improving current standards of care in oncological and viral infection domains. The company's therapeutic approach targets unmet medical needs through systemic immune activation using PRTX007.
For comprehensive scientific publications and clinical trial data, visit [Primmune’s website](https://www.primmunerx.com/).
Competitor Analysis
Primmune operates within a competitive landscape alongside other innovative biotechnology firms.
Key Competitors
1. Neomorph: Based in San Diego, focused on targeted protein degradation to treat diseases caused by 'undruggable' proteins. Highlighted by their collaboration with AbbVie.
2. KBP Biosciences: This New Jersey-based company develops chemical entities for treating cardiovascular, respiratory, inflammatory, and autoimmune diseases.
3. Congruence Therapeutics: Headquartered in Montreal, they utilize computational drug discovery to address protein dynamics and misfolding in rare diseases.
4. TScan Therapeutics: U.S.-based and dedicated to T cell receptor (TCR)-engineered therapies for transformative cancer solutions.
5. GigaGen: Located in San Carlos, California, focuses on recombinant biotherapeutics for immune deficiency and infectious diseases through proprietary single-cell technologies.
These competitors leverage unique technological platforms and strategic collaborations to advance the biopharmaceutical field, with a collective aim of addressing substantial unmet medical needs. Primmune Therapeutics, through its innovative approach to small molecules and strategic partnerships, continues to maintain its competitive stance in this dynamic industry landscape.
